Press Release

23 November 2026 – 17.30

Cessatech strengthens U.S. strategy through broader collaboration with OurPharma and Ventis Pharma

- **New agreement marks a significant step in Cessatech's U.S. commercial strategy and partnership model**
- **Expanded collaboration brings CT001, CT002 and CT004 together under one U.S. strategic partnership**
- **CT004 will follow a direct U.S. FDA/NDA development pathway, targeting a significant commercial opportunity in critical-care medicine**

Copenhagen, Denmark - 23 November 2026 - Cessatech A/S ("Cessatech" or the "Company"), a late-stage paediatric specialty pharmaceutical company, today announces a broader U.S. development and supply agreement with OurPharma LLC and Ventis Pharmaceuticals, Inc. The agreement represents a significant new step in the Company's U.S. strategy, bringing CT001, CT002 and CT004 together within one expanded strategic collaboration. CT001 and CT002 are the initial development and supply priorities, while CT004 will follow a direct U.S. FDA/NDA development pathway.

The collaboration brings together Cessatech's product portfolio and scientific expertise, OurPharma's FDA-registered outsourcing facility in Arkansas and Ventis Pharma's U.S. hospital-market capabilities. The initial priority is to advance product-specific development, manufacturing and supply of CT002 and further accelerate the launch of CT001. Detailed development plans, specifications and commercial terms will be specified for each product. CT004's ongoing clinical study provides a strong foundation for a potentially more streamlined U.S. NDA development pathway, with significant commercial potential in critical-care medicine.

Jes Trygved, CEO of Cessatech, said:
"This is a significant new step in building a stronger and more scalable U.S. business for Cessatech. Bringing CT001, CT002 and CT004 together in one broader collaboration strengthens our hospital-products portfolio and provides a clearer platform for future development and commercialisation. Our immediate focus is on progressing CT001 and CT002 following the early access path, alongside a more dedicated NDA development strategy for CT004, where we see significant commercial potential in critical care. By combining our scientific expertise with the manufacturing and commercial capabilities of OurPharma and Ventis Pharma, we believe we are establishing a solid foundation for the next phase of our U.S. activities."

Join Capital Market session, US strategy – tomorrow 24 November for more details on the new strategy: Register

About CT001, CT002 and CT004

CT001 is an intranasal combination of sufentanil and ketamine developed for acute pain management. CT002 is a ready-to-use intranasal formulation intended for procedural sedation, including imaging procedures. CT004 is an intravenous melatonin programme under clinical development for critical-care applications related to post-anaesthetic agitation.

About OurPharma and Ventis Pharma

OurPharma is a U.S.-based pharmaceutical manufacturer operating an FDA-registered 503B outsourcing facility in Fayetteville, Arkansas, specialising in sterile compounded medicines in the pain-management sector for hospitals and healthcare providers. Ventis Pharma is a U.S. pharmaceutical company focused on developing and commercialising innovative pain-management solutions. Together, the companies bring complementary manufacturing, commercial and hospital-market expertise to support Cessatech's expanding U.S. strategy.

About Cessatech

Cessatech is a late-stage paediatric specialty pharmaceutical company developing hospital medicines for children, with a focus on unmet needs in acute and emergency care. The Company operates a capital-efficient, partnership-driven model

combining a lean team with specialist partners for development, manufacturing and commercial activities. Cessatech is headquartered in Hellerup, Denmark.